Engaging with Lab1636: R&D funding to advance new therapeutics
Learn how Lab1636, a $100M R&D alliance between Harvard University and Deerfield Management, can advance your biomedical innovations.
In 2019, Harvard University and the healthcare investment firm Deerfield Management established a major strategic R&D alliance to speed the development and translation of biomedical and life-science innovations into transformative treatments that can improve life, health, and medical care. Through a newly launched company called Lab1636, Deerfield has committed $100 million in initial funding to support the alliance.
Lab1636 supports faculty-initiated R&D projects throughout various stages of drug discovery and development — for example, enabling studies to:
- explicate the biology of disease
- validate therapeutic targets
- achieve a proof-of-concept necessary for filing an Investigational New Drug (IND) application.
In addition to funding research on campus, Lab1636 may facilitate licenses to outside companies and is equipped to provide substantial support to the launch and growth of new startups dedicated to commercializing Harvard technologies.
About this webinar
Join us on Zoom for this info session with Vivian Berlin, PhD, Managing Director of Strategic Partnerships at Harvard Office of Technology Development (OTD), and Joe Pearlberg, MD, PhD, Vice President of Scientific Affairs at Deerfield. Their presentation will cover the following topics:
- Goals of the Lab1636 alliance and its approach to advancing Harvard researchers' biomedical innovations
- Characteristics of projects that can be spearheaded by the alliance
- Proposal submission process
The presentation will be followed by Q&A.